CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine
CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical...
Clinical trial approval / initiation
JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC
JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed...
AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery
China-based AffaMed Therapeutics has announced that it has received approval from the National Medical Products...
Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it...
Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration...
Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment
China-based Chengdu Hyperway Pharmaceuticals has announced receiving tacit clinical trial approval from the National Medical...
Sirnaomics Commences Phase I Clinical Trial for Factor Xl RNAi Drug STP122G
Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence...
Zelgen Biopharmaceuticals’ ZG006 Earns FDA Approval for Small-Cell Lung Cancer Trial
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical trial approval from...
JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial
China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...
Yiling Pharmaceutical’s XY0206 Advances to Phase III Trial for FLT3-ITD AML
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced its plans to initiate a Phase...
MicuRx Pharmaceuticals Initiates Phase III Study for MRX-4 in Diabetic Foot Infection Treatment
Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study...
TYK Medicines Secures FDA Approval for Next-Generation TKI Clinical Trial
China-based TYK Medicines, Inc. has announced that it has received clinical trial approval from the...
Yantai Dongcheng Pharmaceutical Gets Singapore Regulatory Approval for 177Lu-LNC1004 Phase I Study
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving the green light...
Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...
Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for...
Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for...
AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital
AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and...
Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for Two Clinical Trials
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced two clinical trial approvals from the National...
Hutchison China Meditech Initiates Two Phase II Studies for HMPL-453 and Orpathys
China-based Hutchison China Meditech (HutchMed, NASDAQ: HCM, HKG: 0013) has announced that the first subjects...
Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B
Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases,...